Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer

Cell Death and Differentiation

Volumn 22, Issue 5, 2015, Pages 779-789

  Wu, D W ^a   Huang, C C ^b,c   Chang, S W ^b,c   Chen, T H ^b,c   Lee, H ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 PROTEIN, HUMAN; FLUOROURACIL; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN; PAXILLIN; PROTEIN BCL 2; PXN PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MISSENSE MUTATION; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUTATION, MISSENSE; P21-ACTIVATED KINASES; PAXILLIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES;

EID: 84939944912     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.170     Document Type: Article

References (33)

1. Tarvera T. Cancer Facts & Figures 2012. American Cancer Society (ACS). J Consum Health Internet 2012; 16
2. Cause of death statistics in Taiwan. In: Department of Health EY, ROC (TAIWAN), editor. 2012.
3. Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol 1999; 26: 589-605.
4. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22: 1564-1571.
5. Willett CG, Czito BG, Bendell JC. Radiation therapy in stage II and III rectal cancer. Clin Cancer Res 2007; 13(22 Pt 2): 6903s-6908s.
6. Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ et al. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis 2013; 34: 803-811.
7. Yin H, Zhang Q, Wang X, Li T, Wan Y, Liu Y et al. Role of paxillin in colorectal carcinoma and its relationship to clinicopathological features. Chin Med J 2014; 127: 423-429.
8. Wu DW, Wu TC, Wu JY, Cheng YW, Chen YC, Lee MC et al. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression. Oncogene 2013; 33: 4385-4395.
9. Sorenson CM. Interaction of bcl-2 with paxillin through its BH4 domain is important during ureteric bud branching. J Biol Chem 2004; 279: 11368-11374.
10. Nayal A, Webb DJ, Brown CM, Schaefer EM, Vicente-Manzanares M, Horwitz AR. Paxillin phosphorylation at Ser273 localizes a GIT1-PIX-PAK complex and regulates adhesion and protrusion dynamics. J Cell Biol 2006; 173: 587-589.
11. Breitschopf K, Haendeler J, Malchow P, Zeiher AM, Dimmeler S. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol 2000; 20: 1886-1896.
12. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
13. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
14. Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y et al. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting cyclin D1 and Bcl-2. Carcinogenesis 2012; 33: 220-225.
15. Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S et al. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 1998; 78: 986-992.
16. Zhu H, Guo W, Zhang L, Davis JJ, Teraishi F, Wu S et al. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005; 4: 451-456.
17. Wang C, Youle RJ. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene 2012; 31: 3177-3189.
18. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
19. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 2009; 8: 834-843.
20. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008; 14: 342-346.
21. Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, Crespo P et al. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell 2011; 44: 893-906.
22. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos Jr R, Dayyani F et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19: 657-667.
23. Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M et al. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factorindependent survival and repression of BIM. Oncogene 2008; 27: 7150-7161.
24. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 4286-4293.
25. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18: 39-51.
26. Bielecki A, Roberts J, Mehta R, Raju J. Estrogen receptor-beta mediates the inhibition of DLD-1 human colon adenocarcinoma cells by soy isoflavones. Nutr Cancer 2011; 63: 139-150.
27. Kreeger PK, Mandhana R, Alford SK, Haigis KM, Lauffenburger DA. RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. Cancer Res 2009; 69: 8191-8199.
28. Manne U, Weiss HL, Grizzle WE. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int J Cancer 2000; 89: 423-430.
29. Bosari S, Moneghini L, Graziani D, Lee AK, Murray JJ, Coggi G et al. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995; 26: 534-540.
30. Bhatavdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI, Suthar TP et al. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 1997; 40: 785-790.
31. Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1995; 1: 1103-1110.
32. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 2008; 68: 132-142.
33. Wu DW, Lee MC, Wang J, Chen CY, Cheng YW, Lee H. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer. Oncogene 2013; 33: 1515-1526.